Live Event Coverage
The latest news and dealmakers from global life science partnering events
BIO-Europe Spring® 2017: Atriva repurposes cancer drug candidates to create universal flu treatment
Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, a 2015 startup, explains to Mike Ward, head of pharma content at Informa Pharma Intelligence, how his company is taking kinase inhibitors original
Health tech innovators pitch business ideas to expert panel at BIO-Europe Spring®
The buzz steadily grew as the Health Tech Competition got underway on the last day of BIO-Europe Spring® March 22 in Barcelona. As delegates filed into the competition room, the energy was...
BIO-Europe Spring® 2017: Noxxon CEO discusses partners and cancer combinations
Noxxon CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12, which is being tested as a combination therapy for a number of cancer indications. NOX-A12 i
BIO-Europe Spring® 2017: Celyad VP talks IP issues, development timelines for CAR-T therapies
Georges Rawadi, VP of business development and intellectual property at Celyad, discusses the company's CAR-T pipeline, recently resolved IP issues and the firm's strategy for future clinical developm
BIO-Europe Spring® 2017: Sofinnova chairman discusses entrepreneurial culture change in biotech
Antoine Papiernik is the chairman of Paris-based Sofinnova Partners, a venture capital firm that invests in startups and spinout biotech companies primarily in Europe. He spoke with Luke Timmerman, th
BIO-Europe Spring® 2017: Partnerships are key for rare disease drug discovery and development
What kinds of partnerships are key to getting rare disease research out of the lab and to patients as therapies and cures? Wendy White, Board Chairman of Global Genes, discusses her work on behalf of
BIO-Europe Spring® 2017: Biomunex CEO on earlier deals for cancer drugs
During the recent BIO-Europe Spring partnering conference in Barcelona, Biomunex CEO Pierre-Emmanuel Gerard chats with Scrip about the company's strategy for partnering with pharmas in the cancer drug
BIO-Europe Spring® 2017: Biomunex CSO defines lead compounds, early R&D plans
During BIO-Europe Spring 2017 in Barcelona, Eugene Zhukovsky, chief scientific officer at Biomunex speaks to Scrip about the company's bispecific antibody pipeline and how its candidates are different
BIO-Europe Spring® 2017: Key considerations in microbiome partnering
The human microbiome is garnering research interest across the globe and industry is responding to the growing possibilities of therapeutic developments in a variety of ways, a key aspect of which is
BIO Report: Funding cools down after five-year run while early deals stay hot
Across five metrics for biotech financings tracked by BIO, the sector saw steep drops in 2016 due to uncertainty introduced by political upheavals and regulatory reforms. Yet in each category the...
Biotechs successfully navigate alternative paths to financing
Project awards, strategic venture funds and now crowd-funding offer alternatives to traditional venture funds for emerging biotech companies. Pfizer's new strategic fund or the well-established...
Can pharma afford to cure patients instead of treating them?
Who wants a one-shot therapy that delivers a durable response in patients? What is the price for a cure that payers are willing to pay? Why is pharma turning its attention away from this...
Digital medicine takes small steps toward Big Data
Across a fragmented European landscape multiple programs advance the digitization of data as building blocks for advanced analytics. Read more »
Mounting uncertainty threatens research and innovation in medicines
Regulatory reforms, political upheavals and proposed cuts to research funding create an uncertain and increasingly risky landscape for companies developing new medicines. The life sciences...
POLs: Patient opinion leaders emerge as key to success in orphan drug designation
Orphan drugs are wicked hot. Wall Street loves them. And patients are a powerful force that can make or break a decision to grant that coveted designation for your drug. But don't count on having...
Facing increased complexity, oncology trial sites tighten up procedures
Financing a Phase I trial in oncology is tough, but completing a successful trial for a novel drug candidate is even tougher. An army of specialists is required, and then comes the challenge of...
Startup Slam: Compelling pitch for Peptomyc takes the prize
The third round of this fast-paced parade of presentations pitted 14 promising entrepreneurs in a winner-take-all competition. The reward includes tailored mentoring with the scientists and...
BIO-Europe Spring 2017 kicks off this week in Barcelona
Biotech Showcase™ 2017: Catabasis pursues bifunctional mutation-agnostic approach to DMD
Using its safely metabolized and rationally targeted (SMART) linker platform, Catabasis has identified an NF-κB inhibitor—edasalonexent—as a potential Duchenne muscular dystrophy (DMD) treatment. Spea
Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry
With the Chinese market growing at 10–15% a year, it is poised to be world’s largest by 2026. Tony Chu, co-founder and managing partner at consultants TPP Healthcare, explains to Mike Ward, global dir